ReviewFrontiers in immunology2022
Autoantibodies as biomarkers for breast cancer diagnosis and prognosis.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers.Frontiers in immunology · 2024Pooled it
- The early diagnostic value of lung cancer autoantibodies and tumor markers in lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer.Breast cancer research : BCR · 2026Article
- Development and External Validation of an Interpretable Machine Learning Model Using Routine Blood Biomarkers for Differentiating Malignant Breast Nodules.Journal of inflammation research · 2026Article
- Autoantibodies combined with systemic inflammation markers for predicting bone metastases in non-small cell lung cancer patients.Frontiers in immunology · 2026Article
- Rethinking biomarker strategy in gastric cancer immunotherapy: from tumor to host.Frontiers in immunology · 2026Review
- Integrating Serum Lipid Biomarkers Into Machine Learning for the Differential Diagnosis of Breast Nodules.The breast journal · 2026Article
- Autoantibodies in chronic non-infectious respiratory diseases: a scoping review.Frontiers in immunology · 2026Article
- The B-cell-autoantibody axis in lung cancer immunity.Theranostics · 2026Review
- Breaking Barriers: Immune Checkpoint Inhibitors in Breast Cancer.Pharmaceutics · 2025Review
- A nomogram based on autoantibodies for noninvasive detection of AFP-negative hepatocellular carcinoma: a multicenter study.British journal of cancer · 2025Article
- The assessment of breast cancer biomarkers in diagnosis, prognosis and treatment monitoring: integrated analysis.Journal of cancer research and clinical oncology · 2025Review
- Circulating CHI3L1 autoantibodies serve as a diagnostic biomarker in patients with obstructive sleep apnea.Scientific reports · 2025Article
- Tumor markers level profile in dermatomyositis, systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis and ovarian cancer.European journal of medical research · 2025Article
- The DCDC2/ENO1 axis promotes tumor progression and immune evasion in intrahepatic cholangiocarcinoma via activating FGL1-LAG3 checkpoint.Journal of experimental & clinical cancer research : CR · 2025Article
- The diagnostic value of a breast cancer diagnosis model based on serum MiRNAs and serum tumor markers.World journal of surgical oncology · 2025Article
- A tumor-binding antibody with cross-reactivity to viral antigens.Cancer immunology, immunotherapy : CII · 2025Article
- Use and Comparison of Machine Learning Techniques to Discern the Protein Patterns of Autoantibodies Present in Women with and without Breast Pathology.Journal of proteome research · 2025Article
- Application of Intelligent Response Fluorescent Probe in Breast Cancer.Molecules (Basel, Switzerland) · 2024Review
- The clinical value of combined detection of seven lung cancer-related autoantibodies in assisting the diagnosis of non-small-cell lung cancer.Biomarkers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common cancer in women worldwide and is a substantial public health problem. Screening for breast cancer mainly relies on mammography, which leads to false positives and missed diagnoses and is especially non-sensitive for patients with small tumors and dense breasts. The prognosis of breast cancer is mainly classified by tumor, node, and metastasis (TNM) staging, but this method does not consider the molecular characteristics of the tumor. As the product of the immune response to tumor-associated antigens, autoantibodies can be detected in peripheral blood and can be used as noninvasive, presymptomatic, and low-cost biomarkers. Therefore, autoantibodies can provide a possible supplementary method for breast cancer screening and prognosis classification. This article introduces the methods used to detect peripheral blood autoantibodies and the research progress in the screening and prognosis of breast cancer made in recent years to provide a potential direction for the examination and treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.